๐ง๐ผ๐ฝ ๐ญ๐ฌ ๐บ๐๐ฒ๐น๐ผ๐บ๐ฎ ๐ฝ๐ฎ๐ฝ๐ฒ๐ฟ๐ ๐ผ๐ณ ๐๐ต๐ฒ ๐๐ฒ๐ฎ๐ฟ
2019 was a great year for myeloma. Iโve listed my Top 10 with links to the paper. #MyelomaVR @mtmdphd @Rfonsi1 @grpetersen1 @NorthTxMSG @Mohty_EBMT @SagarLonialMD
Thread/ Countdown below! ๐
2019 was a great year for myeloma. Iโve listed my Top 10 with links to the paper. #MyelomaVR @mtmdphd @Rfonsi1 @grpetersen1 @NorthTxMSG @Mohty_EBMT @SagarLonialMD
Thread/ Countdown below! ๐
#๐ญ๐ฌ ๐ฃ๐ฉ๐ฑ (๐ข๐ฃ๐ง๐๐ ๐๐ฆ๐ฆ๐ )
PVd is a useful regimen with 11 months PFD in relapsed myeloma. @TheLancetOncol @thanosdimop thelancet.com/journals/lanonโฆ
PVd is a useful regimen with 11 months PFD in relapsed myeloma. @TheLancetOncol @thanosdimop thelancet.com/journals/lanonโฆ
#๐ต ๐ ๐๐ฒ๐น๐ผ๐บ๐ฎ ๐ซ๐
Intensification to get deeper response after induction does not improve survival. Important coz we see some centers delay transplant trying to get deeper response. We recommend ASCT after 3-4 cycles. @profghjackson @TheLancetHaem thelancet.com/journals/lanhaโฆ
Intensification to get deeper response after induction does not improve survival. Important coz we see some centers delay transplant trying to get deeper response. We recommend ASCT after 3-4 cycles. @profghjackson @TheLancetHaem thelancet.com/journals/lanhaโฆ
#๐ด ๐๐ง๐ก ๐ฌ๐ณ๐ฌ๐ฎ
No benefit to tandem transplant and no added value of consolidation. Important data applicable specially in the US where we have multiple salvage options. @sgiraltbmtdoc @Phari @ASCO_pubs ascopubs.org/doi/full/10.12โฆ
No benefit to tandem transplant and no added value of consolidation. Important data applicable specially in the US where we have multiple salvage options. @sgiraltbmtdoc @Phari @ASCO_pubs ascopubs.org/doi/full/10.12โฆ
#๐ณ ๐ง๐๐๐ ๐
Antibiotic prophylaxis with levofloxacin in the first 3 months of induction therapy for myeloma is effective. We have changed our guidelines based on this trial. Also recommend Bactrim for PCP prophylaxis. @profghjackson @TheLancetOncol thelancet.com/journals/lanonโฆ
Antibiotic prophylaxis with levofloxacin in the first 3 months of induction therapy for myeloma is effective. We have changed our guidelines based on this trial. Also recommend Bactrim for PCP prophylaxis. @profghjackson @TheLancetOncol thelancet.com/journals/lanonโฆ
#๐ฒ ๐๐๐ฎ๐๐๐
๐ถ๐บ๐ฎ๐ฏ (๐๐๐๐ฅ๐๐)
Isatuximab, a new monoclonal antibody targeting CD38 prolongs PFD in relapsed refractory myeloma. Will hopefully compete with Dara on Cost. @TheLancet thelancet.com/journals/lanceโฆ
Isatuximab, a new monoclonal antibody targeting CD38 prolongs PFD in relapsed refractory myeloma. Will hopefully compete with Dara on Cost. @TheLancet thelancet.com/journals/lanceโฆ
#๐ฑ ๐๐ฒ๐ป๐ฎ๐น๐ถ๐ฑ๐ผ๐บ๐ถ๐ฑ๐ฒ ๐ถ๐ป ๐ฆ๐ ๐ Lenalidomide prolongs time to end organ damage in high risk smoldering multiple myeloma. Together with Spanish data, changes practice. Rd vs DRd randomized trial ongoing now. @SagarLonialMD @eaonc @theNCI @ASCO_pubs
#๐ฐ ๐๐ฎ๐ฟ๐ฎ๐๐๐บ๐๐บ๐ฎ๐ฏ (๐ ๐๐๐)
Daratumumab Len Dex (DRd) is active and is approved for newly diagnosed myeloma. I still prefer VRd for initial therapy. But great data and DRd is a reasonable alternative. @NEJM @szusmani
nejm.org/doi/full/10.10โฆ
Daratumumab Len Dex (DRd) is active and is approved for newly diagnosed myeloma. I still prefer VRd for initial therapy. But great data and DRd is a reasonable alternative. @NEJM @szusmani
nejm.org/doi/full/10.10โฆ
#๐ฏ ๐๐ฅ๐๐๐ ๐ -๐ฎ
Belantamab mafodotin (GSK2857916) active in relapsed refractory myeloma. Response rate 30-35% & PFD 3-5 months is lower than expected. Corneal (eye) toxicity is a concern. We need more data. But promising @TheLancetOncol @SagarLonialMD thelancet.com/journals/lanonโฆ
Belantamab mafodotin (GSK2857916) active in relapsed refractory myeloma. Response rate 30-35% & PFD 3-5 months is lower than expected. Corneal (eye) toxicity is a concern. We need more data. But promising @TheLancetOncol @SagarLonialMD thelancet.com/journals/lanonโฆ
#๐ฎ ๐๐๐ฅ-๐ง
bb2121 Anti-BCMA CAR-T active in relapsed refractory myeloma. Response rate 85%, PFD 12 months. Iโm not sure this is going to be curative, but best single agent efficacy data in myeloma. Very promising. @nejm @NoopurRajeMD @BerdejaJesus nejm.org/doi/full/10.10โฆ
bb2121 Anti-BCMA CAR-T active in relapsed refractory myeloma. Response rate 85%, PFD 12 months. Iโm not sure this is going to be curative, but best single agent efficacy data in myeloma. Very promising. @nejm @NoopurRajeMD @BerdejaJesus nejm.org/doi/full/10.10โฆ
#๐ญ ๐๐๐ฆ๐ฆ๐๐ข๐ฃ๐๐๐
Randomized trial showing efficacy of a 4 drug regimen in myeloma: Dara-VTd. Forerunner of future standard of care. Early evidence of overall survival benefit. Very hard trial to pull off. @TheLancet
thelancet.com/journals/lanceโฆ
Randomized trial showing efficacy of a 4 drug regimen in myeloma: Dara-VTd. Forerunner of future standard of care. Early evidence of overall survival benefit. Very hard trial to pull off. @TheLancet
thelancet.com/journals/lanceโฆ
Honorable mention: Selinexor. I struggled with this. But I couldnโt overcome initial reservations which are well known. The dose approved is not the right dose for practice. Unlikely we can use as a doublet. Need more data. @AjayNookaMD @NEJM nejm.org/doi/full/10.10โฆ
Couple of papers which are not original research that are of importance from 2019.
1. IMWG consensus on imaging. @TheLancetOncol @JHillengass @SLentzsch @szusmani thelancet.com/journals/lanonโฆ
1. IMWG consensus on imaging. @TheLancetOncol @JHillengass @SLentzsch @szusmani thelancet.com/journals/lanonโฆ
2. A commentary by @myelomaMD and myself in @TheLancet warning about the use of surrogate endpoints. @TheLancet @MayoMyeloma thelancet.com/journals/lanceโฆ
I have commented on some of these trials elsewhere. Some links below.
MAIA
MAIA
TEAMM
Lenalidomide for Smoldering myeloma
